JP Stock MarketDetailed Quotes

4536 Santen Pharmaceutical

Watchlist
  • 1699.5
  • +21.5+1.28%
20min DelayTrading Nov 13 15:06 JST
618.66BMarket Cap23.48P/E (Static)

Santen Pharmaceutical Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Santen Pharmaceutical H1 FY2025 Earnings Date

Currency：JPYNov 7, 2024

Estimate
(YoY)		 Actual
(YoY)		 Vs Estimate
(% Chg)
Revenue
--
146.40B
--
+0.41%
EPS
--
52.74
--
+1.58%
Analyst Rating
Buy

Nov 7, 2024

Santen Pharmaceutical Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 3 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: JPY

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/Q4-- / 79.550B--
--2025/Q3-- / 72.798B--
Nov 7, 20242025/Q271.633B / 74.047B--
Aug 6, 20242025/Q174.771B / 73.939B--
May 9, 20242024/Q479.132B / 78.097B--
DatePeriodRevenue/EstimateEarnings Call
--2025/Q4-- / 79.550B--
--2025/Q3-- / 72.798B--
Nov 7, 20242025/Q271.633B / 74.047B--
Aug 6, 20242025/Q174.771B / 73.939B--
May 9, 20242024/Q479.132B / 78.097B--

Unlock Free Earnings Estimates

Santen Pharmaceutical Earnings Reports

  • Santen Pharmaceutical: Confirmation letter

    Nov 11 01:32 ET

  • Santen Pharmaceutical: Half-Yearly Report - Term 113 (2024/04/01 - 2025/03/31)

    Nov 11 01:30 ET

  • Santen Pharmaceutical: Summary of financial results for the 2nd quarter (interim period) for the fiscal year ending March 31, 2025 [IFRS] (consolidated)

    Nov 7 01:00 ET

  • Santen Pharmaceutical: Extraordinary Report

    Oct 8 03:48 ET

    • Read more

    Analysis

    Analyst Rating

    Updated: Nov 7, 2024

    Buy

    • Strong Buy

      50.00%

    • Buy

      20.00%

    • Hold

      30.00%

    • Underperform

      0.00%

    • Sell

      0.00%

    Price Target

    No Data

    Heat List
    JP
    Overall
    Symbol
    Latest Price
    % Chg

    No Data